It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction Patients’ attitudes and subjective experience are crucial in the management of severe mental illness, but their practical value is overlooked. Objectives To identify predictors of future adherence to LAI antipsychotic maintenance treatment of schizophrenia among socio-demographic, clinical, and psychometric characteristics – including Drug Attitude Inventory-10 (DAI-10) and Subjective Well-being under Neuroleptics short form (SWN-K) scores. Methods Retrospective baseline data from 53 clinically stable outpatients with schizophrenia switched from oral to LAI therapy were collected. Patients continuing treatment at the time of analysis (n=29) were compared to those who had discontinued it (n=24). Selected variables were further evaluated in survival analyses. Results Between-group differences are presented in Table 1 (**: p<0.01; *: p<0.05). Cox regression analysis included instruction, employment, hospitalisations, PANSS subscales and DAI-10 scores: a protective role against treatment discontinuation was outlined only for employment (HR 0.16; 95%CI 0.05-0.50) and higher DAI-10 scores (HR 0.85; 95%CI 0.78-0.94). DAI-10 scores delineated distinct adherence trajectories (Figure 1). Conclusions Baseline DAI-10 scores may identify patients at risk of dropout after switching to LAI. Disclosure No significant relationships.Continued treatment Discontinued treatment χ2 or t Treatment persistence (months) 63.79±21.01 23.88±25.80 6.21** Age (years) 39.17±10.11 35.58±13.39 1.11 Male 15 (51.7%) 13 (54.1%) 0.03 Single 20 (69.0%) 15 (62.5%) 0.25 Instruction (years) 13.28±3.31 11.83±3.56 1.53 Employed 20 (69.0%) 7 (29.2%) 8.32** Illness duration (years) 17.69±10.53 13.42±11.36 1.42 Previous hospitalisations 2.10±1.32 2.67±1.86 -1.29 MADRS 13.59±9.06 14.67±8.99 -0.43 YMRS 5.52±5.57 6.00±9.94 -0.22 p-PANSS 12.17±5.20 14.38±6.13 -1.41 n-PANSS 10.90±5.39 15.63±7.93 -2.48* g-PANSS 29.38±10.33 33.63±10.26 -1.49 PANSS 52.66±17.57 63.96±20.61 -2.15* DAI-10 3.86±4.96 -1.13±5.80 3.38** SWN-K 74.93±23.07 81.00±15.60 -1.09
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department Of Health Sciences, University of Florence, Florence, Italy
2 Department Of Mental Health And Addictions, Central Tuscany NHS Trust, Florence, Italy